Organisational Chart

The following figure reflects both the organisational structure of the ICCR and the process flow of dataset development.Org-structure-2.png

Board of Directors

The ICCR Board of Directors comprises representatives from the 5 foundation partners:
European Society of Pathology (ESP), the Royal College of Pathologists UK, the College of American Pathologists (CAP), the Royal College of Pathologists of Australasia (RCPA) and the Canadian Association of Pathologists (CAP-ACP) in association with the Canadian Partnership Against Cancer (CPAC). As well as representatives from our sustaining members:  the American Society of Clinical Pathology (ASCP) and the International Academy of Pathology (IAP) - Australian division.

David Ellis

ICCR President*

Dr David Ellis is a graduate of the University of Melbourne and trained as an anatomical pathologist at Royal Prince Alfred Hospital, Sydney, NSW.  He has a particular interest in haematopathology and established the Victorian Lymphoma Registry in 1992, later to become co-Chair of the Australian Cancer Network Guidelines for the Diagnosis and Management of Lymphoma. He chaired the National Structured Pathology Reporting Project in Australia for 6 years from its inception in 2009, initially as chair of the RCPA Anatomical Pathology Advisory Committee, and subsequently as founding Chair of the RCPA Cancer Services Advisory Committee (CanSAC).  In 2011, Dr Ellis was appointed as inbound liaison to the Cancer Committee of the College of American Pathologists (CAP).  He is Vice President of the Australasian Division of the International Academy of Pathology and a member of the IAP International Executive Committee.  Since 2014 he has represented the ICCR on the UICC TNM Staging Committee in Geneva.
He currently holds an associate professorship at Flinders University, and is CEO of Clinpath Laboratories, South Australia.

John Srigley

Vice-President
Dr. John R. Srigley, MD, FRCPC, FRCPath, FRCPA [Hon.]
Consultant in Oncological and Urological Pathology. 
Dr. Srigley is a graduate of the Faculty of Medicine, University of Toronto. Following oncological pathology training at the University of Toronto and MD Anderson Cancer Centre in Houston, Dr. Srigley was Director of Surgical Pathology at Sunnybrook Health Science Center and Chief of Laboratory Medicine at the Credit Valley Hospital. Currently he is the Chief and Medical Director of the Program of Laboratory Medicine and Genetics at Trillium Health Partners, one of the largest community-academic hospitals in Canada and also a Professor in the Department of Pathology and Molecular Medicine at McMaster University. Dr. Srigley is an international consultant and educator in the fields of oncological and urological pathology and has contributed extensively to the literature. He is an editor/author of three textbooks on urological pathology including the series 3 AFIP Fascicle on Tumors of the Prostate Gland. Dr. Srigley has been an author and member of the international working groups for the  2004 and 2016 WHO Blue Books on  Tumors of the Urinary System and Male Genital Organs. His research interests include clinical-pathological and translational studies of urological cancer, population-level quality initiatives in cancer pathology and the role of the pathologist in cancer control. Dr. Srigley is a Past President of the International Society of Urological Pathologists (ISUP) and the Ontario Association of Pathologists.
 
Dr. Srigley is the Expert Lead for Pathology and Chair of the National Pathology Standards Committee at the Canadian Partnership Against Cancer (CPAC) and represents Canada on the American Joint Committee on Cancer (AJCC).   Dr. Srigley has championed the role of Pathologist as Diagnostic Oncologist and is a strong advocate for population-level standardized synoptic pathology reporting. Dr. Srigley was the inaugural Head of Pathology and Laboratory Medicine at Cancer Care Ontario (2004-2013) and led the clinical implementation of discrete data field synoptic pathology reporting in Ontario. Working with the National Pathology Standards Committee and the Canadian Association of Pathologists, Dr. Srigley was a key leader in securing formal endorsement of the College of American Pathologists(CAP) cancer checklists as pan-Canadian content standards for cancer pathology reporting. He is also a founding board member of the International Collaboration on Cancer Reporting (ICCR) and has provided advice on population-level standardized cancer reporting to CAP, the RCPA Structured Cancer Pathology Reporting Project in Australiasia as well as groups in Poland, Norway and Brazil.
 

Thomas Wheeler

Director
Thomas Wheeler, MD, is board certified in Anatomic Pathology, Clinical Pathology, and Cytopathology and has served over 35 years in academic, consultative, and director/clinical roles with leading University medical centers and healthcare enterprises.

Dr. Wheeler received his medical degree with high honors from Baylor College of Medicine in Houston, Texas, in 1977. At Baylor College of Medicine and Affiliated Hospitals, he completed his residency in Anatomic and Clinical Pathology functioning as Chief Resident in Pathology. For over 29 years, Dr. Wheeler has served on the faculty at Baylor in the Departments of Pathology and Urology; he was appointed Associate Chairman of Pathology in 1995, Professor of Pathology and Urology in 2001. He presently serves as the W.L. Moody, Jr. Professor of Pathology (appointed in 2013), and Chair of the Department of Pathology & Immunology (appointed in 2007).

Dr. Wheeler is a dedicated and outstanding teacher of residents and medical students serving for many years as a lecturer in the second year Pathology Medical School Course at Baylor College of Medicine and as Attending Pathologist at Ben Taub General Hospital.

Along with his many faculty roles, Dr. Wheeler‘s expertise in pathology, particularly genitourinary pathology, is reflected in his membership on Editorial Boards for Human

Pathology, Prostate, American Journal of Surgical Pathology, and Archives of Pathology and Laboratory Medicine. He is also Editor-in-Chief of eMedicine’s online textbook of Pathology and Laboratory Medicine and writes a monthly Pathology and Laboratory Medicine blog for Medscape and is an active member of their Editorial Board.

Dr. Wheeler is an avid clinical researcher with special interests in studies related to diagnosis and prognosis in prostate cancer- his research has anchored the Pathology Department’s role in Baylor College of Medicine’s highly acclaimed prostate cancer program for many years. Since 1992, he has been involved on major research grants totaling over $750,000 including his involvement as the Director of the Pathology Core for Baylor College of Medicine’s Prostate SPORE grant.

Dr. Wheeler has participated on numerous advisory boards and committees for both academic and industry related institutions. He is a well known author and lecturer with over 280 publications and 60 speaker invitations. He has also served as a participant, committee member, and/or officer to a large number of national groups, programs and societies, including the College of American Pathologists, US and Canadian Academy of Pathology, and the Texas Society of Pathologists.

Tim Helliwell

Director
Professor Tim Helliwell graduated in medicine at the University of Cambridge and undertook his training in histopathology in the university Department of Pathology in Liverpool. Since 1984 has been a Consultant Histopathologist at the Royal Liverpool University Hospital (appointed in 1984) and is currently Clinical Director for Cellular Pathology in Liverpool Clinical Laboratories and Honorary Professor of Pathology, University of Liverpool.

As a Consultant Histopathologist in Liverpool for 31 years, I have a wide experience in diagnostic work. In 1997 the Department introduced specialist reporting and since then I have been lead histopathologist for head and neck, thyroid, bone, soft tissue and skeletal muscle pathology. I participate in External Quality Assurance Schemes for orthopaedic (soft tissue and bone) and head and neck pathology and I regularly undertake undergraduate and post-graduate teaching in these areas.

My MD thesis involved studies of techniques to demonstrate damage to skeletal muscle. I am author or co-author of over 126 publications, I have contributed to chapters of the current revision of the WHO Classification of Tumours of the Head and Neck. Ongoing research interests are in the molecular pathology of head and neck cancer and soft tissue sarcomas, and in evidence-based pathology, particularly for head and neck cancer.

I am the lead author for the national pathology guidelines for head and neck cancer published by the Royal College of Pathologists, and was a member of the NICE editorial board for the Improving Outcomes Guidance for Head and Neck Cancer. I was Chair of the Merseyside and Cheshire Pathology Cancer Network Group (2004-7), and helped to shape the development of cancer pathology dataseets as Chair of the Cancer Services Working Group of the Royal College of Pathologists (2005-9). I was sub-specialty adviser in ENT Pathology (2008-2012) to the Royal College of Pathologists and lead pathologist on the head and neck cancer site specific group of the National Cancer Intelligence Network and lead pathologist for review of national cancer dataset (2009-2012). I was an elected member of Council of the Royal College of Pathologists (2012-2014), leading on quality and performance indicators, and in November 2014 was elected as Vice President of the Royal College of Pathologists with responsibilities for training, assessments, examinations and research.

Fred Bosman

Director
Fred Bosman, (1944, the Netherlands), studied Medicine at the University of Leiden (MD 1971), where he also earned his PhD degree (in cytogenetics, 1976) and trained as a pathologist. He was staff pathologist at the University of Leiden (1975-1981), lecturer at the University of Surinam (1974-1975), Professor and chair of Pathology at the Faculty of Medicine of the University of Maastricht (1981-1990) and at the Faculty of Medicine of the Erasmus University in Rotterdam (1990-1995), Director of the University Institute of Pathology and Professor of Pathology at the University Medical Center (CHUV) of Lausanne in Switzerland (1995-2009), now emeritus. He holds or held the position of invited professor at the School of Medicine of the Patan Academy of Health Sciences in Kathmandu (Nepal), the Medical University of Havana (Cuba), the Free University in Brussels (Belgium) and the University of Porto (Portugal). Fred Bosman was member of the Central Committee for the Registration of Medical Specialists in the Netherlands, President of the Dutch Society for Pathology, vice-dean of the Faculty of Medicine in Maastricht, Associate-Dean of education at the Faculty of Biology and Medicine in Lausanne. He is former President of the Society for Histochemistry (now honorary member), former President of the European Society of Pathology (now honorary member), Honorary Fellow of the Royal College of Pathologists (UK) and foreign correspondent of the Royal Netherlands Academy of Sciences.

Fred Bosman’s research activities (combining diagnostic and experimental pathology) focused on the biology of digestive tract cancer, notably Barrett’s esophagus and colorectal cancer, with a strong emphasis on the development of molecular diagnostics. He has written over 350 original publications and over 50 book chapters (H-index 67).

Fred Bosman was member of the Editorial Board of the Dutch Medical Journal (and president of its Society). He is member of the Editorial Board of several international journals in the fields of Pathology and Histochemistry (former Associate Editor of the Journal of Pathology and presently Editor in Chief of Virchows Archiv, European Journal of Pathology). He was one of the Editors of the Dutch textbook ‘Oncology’ and of the Dutch textbook ‘Pathology’.  He is Section Editor ‘Gastro-Intestinal Pathology’ for the online Textbook ‘Pathobiology of Human Disease’.  He is Series-coeditor of the WHO Series ‘Classification of Human Tumours’, the international standard for Tumour classification, and co-editor of the Volume on Tumours of the Digestive Tract.
 

Richard Scolyer

Director
Consultant Pathologist and Co-Director of Research, Melanoma Institute Australia.
Senior Staff Specialist, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney.
Clinical Professor, Sydney Medical School, The University of Sydney.
National Health and Medical Research Council Practitioner Fellow.

Richard Scolyer studied medicine at the University of Tasmania (BMedSci, MBBS). After completing clinical training in Australia and overseas, he undertook pathology training at the Canberra Hospital and at the Royal Prince Alfred Hospital leading to Fellowship of the Royal College of Pathologists of Australasia. Richard is currently Consultant Pathologist and Co-Director of Research, Melanoma Institute Australia; Senior Staff Specialist, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney; and Clinical Professor, The University of Sydney.

Richard has presented on more than 150 occasions at conferences throughout the world, and is a co-author of more than 400 articles and book chapters on melanocytic pathology and related research. In 2006, Richard was awarded the degree of Doctor of Medicine by The University of Sydney for his thesis of publications on melanocytic pathology. He received a NSW Premier's Award for Outstanding Cancer Research in 2009 and 2012 and the Thomson Reuters 2015 Citation Award in the Clinical Medicine category. In 2016, Richard was appointed editor of the 4th Edition of the World Health Organisation Classification of Tumours Skin Tumours volume. He is also Vice Chair of the Melanoma Expert Panel of the American Joint Committee on Cancer (AJCC) for the 8th edition of their Cancer Staging System, an editorial board member of the American Journal of Surgical Pathology, a member of the International Editorial Advisory Board of Histopathology and Senior Associate Editor of Pathology. Richard is currently President of the Australasian Division of the International Academy of Pathology. Together with other MIA colleagues, Richard is chief investigator on a 5 year NHMRC program grant and has a personal Fellowship from the NHMRC.

James L. Wisecarver

Director
James L. Wisecarver, MD, PhD, FASCP
Medical Director, Nebraska Medical Center
Clinical Laboratories
Omaha, Nebraska, USA

James L. Wisecarver, MD, PhD, FASCP, received his doctor of medicine degree from the University of Nebraska Medical Center (UNMC), Omaha, Neb. Dr. Wisecarver earned a bachelor’s degree in biology from Doane College, Crete, Neb., and a doctorate degree in physiology from Creighton University, Omaha. He completed a residency in combined anatomic and clinical pathology at the University of Nebraska Medical Center and then joined the faculty in the Department of Pathology/Microbiology at UNMC as an Assistant Professor in 1990. He was promoted to Associate Professor in 1995 and to Professor in 2002. Currently, he serves as Vice Chair for Clinical Affairs and as Medical Director for the Clinical Laboratories at The Nebraska Medicine. He also serves as the Director of the Human DNA Identification Laboratory at TNMC.

Dr. Wisecarver is currently President-elect of the American Society for Clinical Pathology (ASCP) Board of Directors. "My involvement in ASCP activities dates back to the Council on Continuing Education (CCE) when I became active with the section on diagnostic immunology and molecular pathology. Later, I was elected to the Board of Governors of the ASCP Board of Registry (now Board of Certification). While serving on the Board, I helped organize a new examination committee to develop the molecular biology examination and associated credential that is now being offered through the ASCP Board of Certification." Dr. Wisecarver has also been a member of the ASCP Commission on Science, Technology and Public Policy, the Fellow Council, and the Pathologists Workforce Task Force. He has also chaired the Awards Committee.

Dr. Wisecarver has organized and presented molecular diagnostics workshops offered both through ASCP and the United States and Canada Academy of Pathology (USCAP).
Recently, Dr. Wisecarver celebrated 44 years of marriage with his wife, Patty. They have two grown children and four grandchildren. He enjoys spending time with the grandchildren, along with golfing, fishing and hunting.
 

Sanchia Aranda

Director*
Professor Sanchia Aranda was appointed CEO of Cancer Council Australia in August 2015.

Professor Aranda has more than 30 years’ experience in cancer control as a clinician, researcher, educator and senior healthcare administrator.

From her early career as a Registered Nurse in New Zealand she specialised in cancer and palliative care, completing a Bachelor of Applied Science, a Master of Nursing and a doctoral thesis exploring nurse-patient relationships in cancer and palliative care. Her most recent role was Director of Cancer Services and Information and Deputy CEO at the Cancer Institute NSW.

Professor Aranda is President-elect of the Union for International Cancer Control (the world’s peak member-based cancer organisation) and a former President of the International Society of Nurses in Cancer Care.

As well as being a research fellow at the Peter MacCallum Cancer Centre, she holds academic appointments within the School of Health Sciences, University of Melbourne, and the Faculty of Nursing, University of Sydney.

From a digital technology perspective in her research work Professor Aranda has led studies utilising web and application based programs for support of patients, most recently a randomised trial of a remote symptom assessment system with real time health system connectivity. In her previous role at the Cancer Institute NSW she oversaw the development of technology initiatives in cancer registries including automation of data extracts from clinical information systems into the Central Cancer Registry in NSW. She has also been involved in initiatives to routinely collect patient reported outcomes into clinical information systems. In her CINSW role she established clinical data governance functions and ethical approvals for linked datasets.

In August 2015 she took up the role of CEO of Australia’s peak non-government cancer control organisation. In this role she is a strong independent voice on evidence-based cancer control. She is engaged in all fields of cancer from primary prevention through to survivorship and advanced care, and has a particular professional interest in improved ways to care for and support cancer patients and enhanced use of administrative datasets to understand clinical variation and to improve our cancer system.

She is a regular commentator on cancer issues in Australia media.

Professor Aranda’s role in cancer control has been recognised nationally and internationally, and in 2013 she was named the 4th Peter MacCallum Cancer Centre Distinguished Fellow for her contributions to cancer nursing. In 2016 she received the International Society of Nurses in Cancer Care’s Distinguish Merit Award for her contributions to cancer nursing.
*Note it is a requirement of Australian law that companies incorporating in Australia have 2 Australian resident directors.

Additional directors may be added to the Board of Directors either by becoming sustaining (financially supporting) members or by vote from the general membership (maximum 2 places).

The ICCR Board has strategic oversight of all ICCR operations and financial and legal responsibility for the running of the ICCR and is governed by a charter.
 

Dataset Steering Committee (DSC)

The ICCR DSC has responsibility for all activities relating to the development of ICCR cancer datasets. Membership is as follows:
 
Directors
  • David Ellis
  • Thomas Wheeler
  • Tim Helliwell
  • John Srigley
  • Fred Bosman
  • Richard Scolyer
Sustaining member representatives
  • James Kench, RCPA, Australia
  • Thomas Baker, CAP, USA
  • Brian Rous, RCPath, UK
  • Paul Barrett, RCPath, UK
  • David Driman, CAP-ACP, Canada
  • Trishe Leong, IAP-Australasian Division, Australia
  • Iris Nagtegaal, ESP
  • Alexandra (Ali) Brown, ASCP
Strategic partner organisation representatives
  • Les Mery, International Association of Cancer Registries (IACR)
  • Thomas Gevaert, EORTC
  • Pieter Demetter, EORTC
  • Yan Liu, EORTC
  • Emilie Varin, EORTC
  • Maria Urbanowicz, EORTC
Project management support
  • Meagan Judge, RCPA
  • Fleur Webster, ICCR
  • Beth Chmara, CAP
  • Kelly Goodrich, CAP
  • Doug Murphy, CAP
Ex-officio members
  • George Birdsong, PERT, CAP
  • Samantha Spencer, CAP
The Terms of Reference for the ICCR Dataset Steering Committee are available for review.
 

Editorial/Quality Committee (EQ)

The purpose of the ICCR EQ is to provide an independent review of each ICCR dataset prior to public consultation to ensure it adheres to ICCR standards. Currently this committee’s function is undertaken by the DSC.

The Terms of Reference for the planned ICCR EQ Committee are available for review.
 

Dataset Authoring CommitteeS (DAC)

DAC’s are convened as needed for the development of specific datasets.

The ICCR Dataset Steering Committee, having selected a specific cancer dataset for development, will invite an appropriately qualified pathologist to take on the role of Chair and a Dataset Authoring Committee will then be convened.